Cumberland Pharmaceuticals Inc. reported a 10% increase in Q2 revenue, despite facing challenges such as net losses and high operating expenses.

Cumberland Pharmaceuticals Inc. is facing significant financial challenges, including a negative price-to-earnings ratio and volatile stock performance, raising concerns about its sustainability and growth prospects.